+39 02 610346.1 - info@newron.com

2020

2020

Newron Pharmaceuticals provides clinical and business update

 

Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome

 

Newron Acknowledges Definitive Agreement Between US WorldMeds and Supernus Pharmaceuticals Regarding XADAGO® (safinamide)

Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

 

Newron AGM Result and Clinical and Business Update

 

Newron updates on STARS study FDA interaction

 

Newron announces 2019 financial results and provides outlook for 2020

 

Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

 

Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA